Rhythm Pharmaceuticals is making big financial moves to fund its experimental obesity drug, bivamelagon. The biotech company has renegotiated its licensing deal with South Korean chemical giant LG Chem and secured up to $750 million in new debt financing from private equity firms KKR and Blackstone.
The restructuring is designed to give Rhythm more financial runway and reduce future payout obligations, as it pushes bivamelagon through clinical trials and toward potential commercialization.
What's changing in the LG Chem deal?
Under the revised agreement, LG Chem's royalties on bivamelagon will drop to 1% starting in January 2029. Previously, LG Chem was entitled to higher royalty payments as part of the original licensing arrangement. The exact terms of the original deal were not disclosed in the brief, but the reduction is significant enough to materially improve Rhythm's future profit margins if the drug succeeds.
Bivamelagon is an experimental treatment targeting the melanocortin-4 receptor (MC4R), a pathway involved in regulating appetite and energy balance. It's being developed for rare genetic forms of obesity, a niche but serious condition where patients often struggle with severe weight gain from an early age.
By cutting LG Chem's royalty rate, Rhythm keeps a larger share of any future sales. That's a common strategy for biotechs that need to show investors a clearer path to profitability, especially when they're burning cash on expensive late-stage trials.
New financing from KKR and Blackstone
To fund the drug's development, Rhythm has lined up up to $750 million in debt financing from KKR, with Blackstone also involved. Debt financing is different from selling new shares—it doesn't dilute existing shareholders, but it does add interest payments and repayment obligations.
For a biotech with no approved product yet, this kind of financing is a bet on future success. Lenders like KKR and Blackstone are typically willing to take on that risk if they see strong clinical data and a large addressable market. Obesity drugs have become one of the hottest areas in pharma, with blockbuster treatments like Ozempic and Wegovy generating billions in sales.
Rhythm's focus on rare genetic obesity sets it apart from the broader weight-loss market, which is dominated by GLP-1 drugs. Bivamelagon works through a different mechanism, which could make it an option for patients who don't respond to or can't tolerate GLP-1s.
What it means for investors
For everyday investors, this news is a reminder that biotech investing is a high-risk, high-reward game. Rhythm is still in the development stage, meaning there's no guarantee bivamelagon will reach the market. Clinical trials can fail, regulators can delay approvals, and competitors can move faster.
The financing deal gives Rhythm more time and money to prove its drug works, which reduces the near-term risk of running out of cash—a common killer of small biotechs. But it also adds debt, which means the company will need to generate revenue eventually to cover those obligations.
Investors should also note the involvement of KKR and Blackstone, two of the world's largest alternative asset managers. Their willingness to back Rhythm suggests they see potential in the drug, but it's not a guarantee of success. Private equity firms often structure deals to protect themselves, sometimes with collateral or conversion rights that could affect common shareholders.
The royalty cut to LG Chem is a positive for Rhythm's long-term economics, but it also signals that LG Chem is willing to accept a smaller future payout in exchange for something now—likely a lump-sum payment or other consideration. That trade-off is worth watching, as it could impact Rhythm's cash position.
Looking ahead
Rhythm's next major catalyst will be clinical trial data for bivamelagon. Positive results could send the stock higher, while setbacks could erase much of the recent optimism. Investors should also watch for updates on the financing's final terms and any regulatory milestones.
For those considering an investment in Rhythm or similar biotechs, it's important to understand that these companies often see huge swings in share price based on trial outcomes. Diversification is key—biotech stocks should only be a small part of a broader portfolio.
As the obesity drug market continues to heat up, Rhythm's strategy of focusing on rare genetic forms could carve out a valuable niche. But until the drug is approved and selling, the company remains a speculative bet.
